Eisai Rufinamide Study Reports 33 Percent Reduction In Epileptic Seizures
This article was originally published in PharmAsia News
Executive Summary
Eisai's rufinamide reduced the total frequency of seizures in patients with Lennox-Gastaut Syndrome by approximately 33 percent compared to placebo in study results published in the May 20 issue of Neurology